Global Community Acquired Pneumonia (CAP) Market Insights and Forecast to 2031

Report ID: 1451257 | Published Date: Jan 2025 | No. of Page: 109 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Chest X-ray/Radiography
        1.2.3 Sputum Gram Stain and/or Culture
        1.2.4 Blood Cultures
    1.3 Market by Application
        1.3.1 Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals and Clinics
        1.3.3 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Community Acquired Pneumonia (CAP) Market Perspective (2017-2028)
    2.2 Community Acquired Pneumonia (CAP) Growth Trends by Region
        2.2.1 Community Acquired Pneumonia (CAP) Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Community Acquired Pneumonia (CAP) Historic Market Size by Region (2017-2022)
        2.2.3 Community Acquired Pneumonia (CAP) Forecasted Market Size by Region (2023-2028)
    2.3 Community Acquired Pneumonia (CAP) Market Dynamics
        2.3.1 Community Acquired Pneumonia (CAP) Industry Trends
        2.3.2 Community Acquired Pneumonia (CAP) Market Drivers
        2.3.3 Community Acquired Pneumonia (CAP) Market Challenges
        2.3.4 Community Acquired Pneumonia (CAP) Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Community Acquired Pneumonia (CAP) Players by Revenue
        3.1.1 Global Top Community Acquired Pneumonia (CAP) Players by Revenue (2017-2022)
        3.1.2 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Players (2017-2022)
    3.2 Global Community Acquired Pneumonia (CAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Community Acquired Pneumonia (CAP) Revenue
    3.4 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio
        3.4.1 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Community Acquired Pneumonia (CAP) Revenue in 2021
    3.5 Community Acquired Pneumonia (CAP) Key Players Head office and Area Served
    3.6 Key Players Community Acquired Pneumonia (CAP) Product Solution and Service
    3.7 Date of Enter into Community Acquired Pneumonia (CAP) Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Community Acquired Pneumonia (CAP) Breakdown Data by Type
    4.1 Global Community Acquired Pneumonia (CAP) Historic Market Size by Type (2017-2022)
    4.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Type (2023-2028)
5 Community Acquired Pneumonia (CAP) Breakdown Data by Application
    5.1 Global Community Acquired Pneumonia (CAP) Historic Market Size by Application (2017-2022)
    5.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Community Acquired Pneumonia (CAP) Market Size (2017-2028)
    6.2 North America Community Acquired Pneumonia (CAP) Market Size by Type
        6.2.1 North America Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022)
        6.2.2 North America Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028)
        6.2.3 North America Community Acquired Pneumonia (CAP) Market Share by Type (2017-2028)
    6.3 North America Community Acquired Pneumonia (CAP) Market Size by Application
        6.3.1 North America Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022)
        6.3.2 North America Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028)
        6.3.3 North America Community Acquired Pneumonia (CAP) Market Share by Application (2017-2028)
    6.4 North America Community Acquired Pneumonia (CAP) Market Size by Country
        6.4.1 North America Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022)
        6.4.2 North America Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Community Acquired Pneumonia (CAP) Market Size (2017-2028)
    7.2 Europe Community Acquired Pneumonia (CAP) Market Size by Type
        7.2.1 Europe Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022)
        7.2.2 Europe Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028)
        7.2.3 Europe Community Acquired Pneumonia (CAP) Market Share by Type (2017-2028)
    7.3 Europe Community Acquired Pneumonia (CAP) Market Size by Application
        7.3.1 Europe Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022)
        7.3.2 Europe Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028)
        7.3.3 Europe Community Acquired Pneumonia (CAP) Market Share by Application (2017-2028)
    7.4 Europe Community Acquired Pneumonia (CAP) Market Size by Country
        7.4.1 Europe Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022)
        7.4.2 Europe Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size (2017-2028)
    8.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type
        8.2.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Community Acquired Pneumonia (CAP) Market Share by Type (2017-2028)
    8.3 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application
        8.3.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Community Acquired Pneumonia (CAP) Market Share by Application (2017-2028)
    8.4 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region
        8.4.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Community Acquired Pneumonia (CAP) Market Size (2017-2028)
    9.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Type
        9.2.1 Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022)
        9.2.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028)
        9.2.3 Latin America Community Acquired Pneumonia (CAP) Market Share by Type (2017-2028)
    9.3 Latin America Community Acquired Pneumonia (CAP) Market Size by Application
        9.3.1 Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022)
        9.3.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028)
        9.3.3 Latin America Community Acquired Pneumonia (CAP) Market Share by Application (2017-2028)
    9.4 Latin America Community Acquired Pneumonia (CAP) Market Size by Country
        9.4.1 Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022)
        9.4.2 Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size (2017-2028)
    10.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type
        10.2.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Community Acquired Pneumonia (CAP) Market Share by Type (2017-2028)
    10.3 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application
        10.3.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Community Acquired Pneumonia (CAP) Market Share by Application (2017-2028)
    10.4 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country
        10.4.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Pfizer
        11.1.1 Pfizer Company Details
        11.1.2 Pfizer Business Overview
        11.1.3 Pfizer Community Acquired Pneumonia (CAP) Introduction
        11.1.4 Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.1.5 Pfizer Recent Developments
    11.2 Astrazeneca
        11.2.1 Astrazeneca Company Details
        11.2.2 Astrazeneca Business Overview
        11.2.3 Astrazeneca Community Acquired Pneumonia (CAP) Introduction
        11.2.4 Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.2.5 Astrazeneca Recent Developments
    11.3 Bioaegis Therapeutics
        11.3.1 Bioaegis Therapeutics Company Details
        11.3.2 Bioaegis Therapeutics Business Overview
        11.3.3 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Introduction
        11.3.4 Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.3.5 Bioaegis Therapeutics Recent Developments
    11.4 Biotest
        11.4.1 Biotest Company Details
        11.4.2 Biotest Business Overview
        11.4.3 Biotest Community Acquired Pneumonia (CAP) Introduction
        11.4.4 Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.4.5 Biotest Recent Developments
    11.5 C10 Pharma
        11.5.1 C10 Pharma Company Details
        11.5.2 C10 Pharma Business Overview
        11.5.3 C10 Pharma Community Acquired Pneumonia (CAP) Introduction
        11.5.4 C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.5.5 C10 Pharma Recent Developments
    11.6 Kyorin Pharmaceutical
        11.6.1 Kyorin Pharmaceutical Company Details
        11.6.2 Kyorin Pharmaceutical Business Overview
        11.6.3 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Introduction
        11.6.4 Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.6.5 Kyorin Pharmaceutical Recent Developments
    11.7 Melinta Therapeutics
        11.7.1 Melinta Therapeutics Company Details
        11.7.2 Melinta Therapeutics Business Overview
        11.7.3 Melinta Therapeutics Community Acquired Pneumonia (CAP) Introduction
        11.7.4 Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.7.5 Melinta Therapeutics Recent Developments
    11.8 Merck
        11.8.1 Merck Company Details
        11.8.2 Merck Business Overview
        11.8.3 Merck Community Acquired Pneumonia (CAP) Introduction
        11.8.4 Merck Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.8.5 Merck Recent Developments
    11.9 Nabriva Therapeutics
        11.9.1 Nabriva Therapeutics Company Details
        11.9.2 Nabriva Therapeutics Business Overview
        11.9.3 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Introduction
        11.9.4 Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.9.5 Nabriva Therapeutics Recent Developments
    11.10 Paratek Pharmaceuticals
        11.10.1 Paratek Pharmaceuticals Company Details
        11.10.2 Paratek Pharmaceuticals Business Overview
        11.10.3 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Introduction
        11.10.4 Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022)
        11.10.5 Paratek Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
List of Tables
    Table 1. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Chest X-ray/Radiography
    Table 3. Key Players of Sputum Gram Stain and/or Culture
    Table 4. Key Players of Blood Cultures
    Table 5. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 6. Global Community Acquired Pneumonia (CAP) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Community Acquired Pneumonia (CAP) Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Community Acquired Pneumonia (CAP) Market Share by Region (2017-2022)
    Table 9. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Community Acquired Pneumonia (CAP) Market Share by Region (2023-2028)
    Table 11. Community Acquired Pneumonia (CAP) Market Trends
    Table 12. Community Acquired Pneumonia (CAP) Market Drivers
    Table 13. Community Acquired Pneumonia (CAP) Market Challenges
    Table 14. Community Acquired Pneumonia (CAP) Market Restraints
    Table 15. Global Community Acquired Pneumonia (CAP) Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Community Acquired Pneumonia (CAP) Revenue Share by Players (2017-2022)
    Table 17. Global Top Community Acquired Pneumonia (CAP) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2021)
    Table 18. Ranking of Global Top Community Acquired Pneumonia (CAP) Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Community Acquired Pneumonia (CAP) Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Community Acquired Pneumonia (CAP) Product Solution and Service
    Table 22. Date of Enter into Community Acquired Pneumonia (CAP) Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2017-2022)
    Table 26. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2023-2028)
    Table 28. Global Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Community Acquired Pneumonia (CAP) Revenue Share by Application (2017-2022)
    Table 30. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Community Acquired Pneumonia (CAP) Revenue Share by Application (2023-2028)
    Table 32. North America Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022) & (US$ Million)
    Table 33. North America Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028) & (US$ Million)
    Table 34. North America Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022) & (US$ Million)
    Table 35. North America Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028) & (US$ Million)
    Table 36. North America Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022) & (US$ Million)
    Table 37. North America Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Europe Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022) & (US$ Million)
    Table 39. Europe Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028) & (US$ Million)
    Table 40. Europe Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022) & (US$ Million)
    Table 41. Europe Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028) & (US$ Million)
    Table 42. Europe Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Europe Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Asia Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Asia Pacific Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2023-2028) & (US$ Million)
    Table 50. Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022) & (US$ Million)
    Table 55. Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028) & (US$ Million)
    Table 56. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Pfizer Company Details
    Table 63. Pfizer Business Overview
    Table 64. Pfizer Community Acquired Pneumonia (CAP) Product
    Table 65. Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 66. Pfizer Recent Developments
    Table 67. Astrazeneca Company Details
    Table 68. Astrazeneca Business Overview
    Table 69. Astrazeneca Community Acquired Pneumonia (CAP) Product
    Table 70. Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 71. Astrazeneca Recent Developments
    Table 72. Bioaegis Therapeutics Company Details
    Table 73. Bioaegis Therapeutics Business Overview
    Table 74. Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Product
    Table 75. Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 76. Bioaegis Therapeutics Recent Developments
    Table 77. Biotest Company Details
    Table 78. Biotest Business Overview
    Table 79. Biotest Community Acquired Pneumonia (CAP) Product
    Table 80. Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 81. Biotest Recent Developments
    Table 82. C10 Pharma Company Details
    Table 83. C10 Pharma Business Overview
    Table 84. C10 Pharma Community Acquired Pneumonia (CAP) Product
    Table 85. C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 86. C10 Pharma Recent Developments
    Table 87. Kyorin Pharmaceutical Company Details
    Table 88. Kyorin Pharmaceutical Business Overview
    Table 89. Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Product
    Table 90. Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 91. Kyorin Pharmaceutical Recent Developments
    Table 92. Melinta Therapeutics Company Details
    Table 93. Melinta Therapeutics Business Overview
    Table 94. Melinta Therapeutics Community Acquired Pneumonia (CAP) Product
    Table 95. Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 96. Melinta Therapeutics Recent Developments
    Table 97. Merck Company Details
    Table 98. Merck Business Overview
    Table 99. Merck Community Acquired Pneumonia (CAP) Product
    Table 100. Merck Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 101. Merck Recent Developments
    Table 102. Nabriva Therapeutics Company Details
    Table 103. Nabriva Therapeutics Business Overview
    Table 104. Nabriva Therapeutics Community Acquired Pneumonia (CAP) Product
    Table 105. Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 106. Nabriva Therapeutics Recent Developments
    Table 107. Paratek Pharmaceuticals Company Details
    Table 108. Paratek Pharmaceuticals Business Overview
    Table 109. Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Product
    Table 110. Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2017-2022) & (US$ Million)
    Table 111. Paratek Pharmaceuticals Recent Developments
    Table 112. Research Programs/Design for This Report
    Table 113. Key Data Information from Secondary Sources
    Table 114. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Community Acquired Pneumonia (CAP) Market Share by Type: 2021 VS 2028
    Figure 2. Chest X-ray/Radiography Features
    Figure 3. Sputum Gram Stain and/or Culture Features
    Figure 4. Blood Cultures Features
    Figure 5. Global Community Acquired Pneumonia (CAP) Market Share by Application: 2021 VS 2028
    Figure 6. Hospitals and Clinics Case Studies
    Figure 7. Others Case Studies
    Figure 8. Community Acquired Pneumonia (CAP) Report Years Considered
    Figure 9. Global Community Acquired Pneumonia (CAP) Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 10. Global Community Acquired Pneumonia (CAP) Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Community Acquired Pneumonia (CAP) Market Share by Region: 2021 VS 2028
    Figure 12. Global Community Acquired Pneumonia (CAP) Market Share by Players in 2021
    Figure 13. Global Top Community Acquired Pneumonia (CAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2021)
    Figure 14. The Top 10 and 5 Players Market Share by Community Acquired Pneumonia (CAP) Revenue in 2021
    Figure 15. North America Community Acquired Pneumonia (CAP) Market Size YoY (2017-2028) & (US$ Million)
    Figure 16. North America Community Acquired Pneumonia (CAP) Market Size Market Share by Type (2017-2028)
    Figure 17. North America Community Acquired Pneumonia (CAP) Market Size Market Share by Application (2017-2028)
    Figure 18. North America Community Acquired Pneumonia (CAP) Market Size Share by Country (2017-2028)
    Figure 19. United States Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Canada Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Community Acquired Pneumonia (CAP) Market Size YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Community Acquired Pneumonia (CAP) Market Size Market Share by Type (2017-2028)
    Figure 23. Europe Community Acquired Pneumonia (CAP) Market Size Market Share by Application (2017-2028)
    Figure 24. Europe Community Acquired Pneumonia (CAP) Market Size Share by Country (2017-2028)
    Figure 25. Germany Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. France Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. U.K. Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Italy Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Russia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Nordic Countries Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Community Acquired Pneumonia (CAP) Market Size YoY (2017-2028) & (US$ Million)
    Figure 32. Asia Pacific Community Acquired Pneumonia (CAP) Market Size Market Share by Type (2017-2028)
    Figure 33. Asia Pacific Community Acquired Pneumonia (CAP) Market Size Market Share by Application (2017-2028)
    Figure 34. Asia Pacific Community Acquired Pneumonia (CAP) Market Size Share by Region (2017-2028)
    Figure 35. China Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Japan Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. South Korea Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Southeast Asia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. India Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Australia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Latin America Community Acquired Pneumonia (CAP) Market Size YoY (2017-2028) & (US$ Million)
    Figure 42. Latin America Community Acquired Pneumonia (CAP) Market Size Market Share by Type (2017-2028)
    Figure 43. Latin America Community Acquired Pneumonia (CAP) Market Size Market Share by Application (2017-2028)
    Figure 44. Latin America Community Acquired Pneumonia (CAP) Market Size Share by Country (2017-2028)
    Figure 45. Mexico Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Brazil Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Middle East & Africa Community Acquired Pneumonia (CAP) Market Size YoY (2017-2028) & (US$ Million)
    Figure 48. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size Market Share by Type (2017-2028)
    Figure 49. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size Market Share by Application (2017-2028)
    Figure 50. Middle East and Africa Community Acquired Pneumonia (CAP) Market Size Share by Country (2017-2028)
    Figure 51. Turkey Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. UAE Community Acquired Pneumonia (CAP) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Pfizer Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 55. Astrazeneca Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 56. Bioaegis Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 57. Biotest Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 58. C10 Pharma Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 59. Kyorin Pharmaceutical Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 60. Melinta Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 61. Merck Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 62. Nabriva Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 63. Paratek Pharmaceuticals Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2017-2022)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
Astrazeneca
Bioaegis Therapeutics
Biotest
C10 Pharma
Kyorin Pharmaceutical
Melinta Therapeutics
Merck
Nabriva Therapeutics
Paratek Pharmaceuticals
Frequently Asked Questions
Community Acquired Pneumonia (CAP) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Community Acquired Pneumonia (CAP) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Community Acquired Pneumonia (CAP) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports